Compugen: Rilvegostomig expected to progress into Phase 3 this year

Compugen (CGEN) reported that rilvegostomig, AstraZeneca’s (AZN) bi-specific antibody derived from Compugen’s COM902, is expected to progress into Phase 3 this year. AstraZeneca announced plans to initiate a Phase 3 trial for rilvegostomig, a PD-1/TIGIT bi-specific antibody and is also developing an expanded Phase 2 program.